title: Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
abstract: Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.
authors.affiliation: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.
authors.forename: Viet Loan
authors.initials: VL
authors.lastname: Dao Thi
authors.affiliation: Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
authors.forename: Yannick
authors.initials: Y
authors.lastname: Debing
authors.affiliation: Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.
authors.forename: Xianfang
authors.initials: X
authors.lastname: Wu
authors.affiliation: Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.
authors.forename: Charles M
authors.initials: CM
authors.lastname: Rice
authors.affiliation: Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
authors.forename: Johan
authors.initials: J
authors.lastname: Neyts
authors.affiliation: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Darius.Moradpour@chuv.ch.
authors.forename: Darius
authors.initials: D
authors.lastname: Moradpour
authors.affiliation: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Jerome.Gouttenoire@chuv.ch.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Gouttenoire
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002908:Chronic Disease; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D016751:Hepatitis E / Q000188:drug therapy*; D016752:Hepatitis E virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D012367:RNA, Viral / Q000187:drug effects / Q000502:physiology; D012254:Ribavirin / Q000008:administration & dosage* / Q000494:pharmacology; D000069474:Sofosbuvir / Q000008:administration & dosage* / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: Antiviral; Chronic Hepatitis; Immunosuppression; Polymerase Inhibitor